Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial

University of Athens School of Medicine, Alexandra Hospital, Athens, Greece
University Hospital Leuven, Leuven, Belgium
Faculty Hospital FN, Brno, and University of Ostrava School of Medicine, Ostrava, Czech Republic
University of Münster, Münster, Germany
Università di Roma Sapienza, Rome, Italy
Celgene GmbH, Munich, Germany
Oxford Outcomes, an ICON Plc Company, Oxford, UK
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Summit, NJ, USA
University of Turin, Turin, Italy
Vol. 98 No. 5 (2013): May, 2013